A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...

BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Acurx Pharmaceuticals Inc ACXP shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session. The move may reflect continued investor reaction to ...

An NHS trust’s leaders will this week be told that there have been “multiple outbreaks” and periods of increased incidence of ...

Acurx Pharmaceuticals Inc. ACXP shares are pulling back in premarket trading Thursday after the late-stage biopharmaceutical company rallied 107.93% to close sharply higher in Wednesday's session.

莱顿的科学家们开发出一种名为EVG7的新型抗生素，仅需极小剂量即可对抗危险的肠道细菌——艰难梭菌（Clostridioides difficile, C. difficile）。 这种疗法似乎还能大大降低感染复发的可能性，而复发是目前抗生素治疗中常见的问题。相关研究结果已发表在《自然·通讯》（Nature Communications）杂志上。

Scientists have identified why some gut microbes successfully stay in the gut after fecal transplants, while others are much more transient. The King's College London discovery could help make the ...